 |
22 Diseases |  |
2 Trials |
|
2 Trials |  |
188 News |  |
| «123 |
- pracinostat (SB939) / Helsinn, MEI, Menarini
Trial completion, Metastases: A Study of SB939 in Patients With Translocation-Associated Recurrent/Metastatic Sarcomas (clinicaltrials.gov) - Jan 15, 2014
P2, N=24, Completed, Sponsor: NCIC Clinical Trials Group
Active, not recruiting --> Completed
- |||| pracinostat (SB939) / Helsinn, MEI, Menarini
Enrollment open: Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA (clinicaltrials.gov) - Dec 9, 2013
P2, N=76, Recruiting, Sponsor: MEI Pharma, Inc.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| pracinostat (SB939) / Helsinn, MEI, Menarini
New P2 trial: Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA (clinicaltrials.gov) - Nov 21, 2013
P2, N=76, Recruiting, Sponsor: MEI Pharma, Inc.
- | pracinostat (SB939) / Helsinn, MEI, Menarini
Enrollment open, Combination therapy: Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Oct 20, 2013
P2, N=50, Recruiting, Sponsor: MEI Pharma, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | pracinostat (SB939) / Helsinn, MEI, Menarini
New P2 trial, Combination therapy: Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Jul 29, 2013
P2, N=50, Recruiting, Sponsor: MEI Pharma, Inc.
- pracinostat (SB939) / Helsinn, MEI, Menarini
Enrollment change, Metastases: A Study of SB939 in Patients With Translocation-Associated Recurrent/Metastatic Sarcomas (clinicaltrials.gov) - Jul 21, 2013
P2, N=24, Completed, Sponsor: NCIC Clinical Trials Group
Not yet recruiting --> Recruiting N=32 --> 24
- pracinostat (SB939) / Helsinn, MEI, Menarini
Enrollment change: A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia (clinicaltrials.gov) - Jun 19, 2013
P1, N=12, Completed, Sponsor: NCIC Clinical Trials Group
N=32 --> 24 N=39 --> 12
- ||||| pracinostat (SB939) / Helsinn, MEI, Menarini
New P2 trial, Combination therapy: Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome (clinicaltrials.gov) - Jun 6, 2013
P2, N=100, Recruiting, Sponsor: MEI Pharma, Inc.
- | pracinostat (SB939) / Helsinn, MEI, Menarini
Enrollment change, Epigenetic controller: Study of SB939 in Subjects With Myelofibrosis (clinicaltrials.gov) - Nov 13, 2012
P2, N=23, Completed, Sponsor: M.D. Anderson Cancer Center
N=39 --> 12 N=41 --> 23
- | pracinostat (SB939) / Helsinn, MEI, Menarini
Trial completion, Epigenetic controller: Study of SB939 in Subjects With Myelofibrosis (clinicaltrials.gov) - Nov 13, 2012
P2, N=23, Completed, Sponsor: M.D. Anderson Cancer Center
N=41 --> 23 Active, not recruiting --> Completed
- ||| pracinostat (SB939) / Helsinn, MEI, Menarini
Trial completion, Metastases: A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine (clinicaltrials.gov) - Apr 18, 2012
P1, N=85, Completed, Sponsor: S*BIO
Active, not recruiting --> Completed Active, not recruiting --> Completed
- pracinostat (SB939) / Helsinn, MEI, Menarini
Enrollment closed, Metastases: SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer (clinicaltrials.gov) - Nov 6, 2011
P2, N=32, Active, not recruiting, Sponsor: NCIC Clinical Trials Group
Active, not recruiting --> Completed Recruiting --> Active, not recruiting